A recent paper on Lac-Phe that people may be interested in:
Sprint Signal: The Molecule Your Muscles Fire Off When You Go Hard, and Why Metformin Fakes It
Hard exercise floods the bloodstream with a small molecule called Lac-Phe, built by stitching lactate to the amino acid phenylalanine. In mice, injecting Lac-Phe cuts food intake by roughly half, drops body weight about 7 percent in ten days, and strips fat without touching lean mass or making the animals sick, anxious, or sluggish. It works by shutting down hunger-driving AgRP neurons in the hypothalamus through ATP-sensitive potassium channels, a route independent of leptin, ghrelin, and GLP-1. The same molecule is now shown to be a major mediator of metformin’s long-mysterious weight-loss effect, and it is produced in the gut rather than muscle when metformin is the trigger. This review consolidates the biosynthesis pathway (the enzyme CNDP2), the export route (SLC17A1 and SLC17A3 transporters), the brain circuit, and a widening set of biomarker and therapeutic claims spanning sepsis, glaucoma, phenylketonuria, colitis, and spinal cord injury. Human evidence remains almost entirely correlational.
For decades the phrase “exercise is medicine” has been a slogan in search of a molecule. Researchers knew that hard physical work reshapes appetite, body composition, and metabolic risk, but the messenger carrying that signal from working muscle to the brain stayed hidden. Lac-Phe is now the strongest candidate anyone has produced.
The molecule is chemically unglamorous. It is lactate, the byproduct that accumulates when muscles work beyond their oxidative capacity, chemically joined to phenylalanine, a common dietary amino acid. An enzyme called CNDP2 performs the join. What makes it interesting is the response curve. After an all-out treadmill sprint, mouse plasma Lac-Phe rises roughly sevenfold. In racehorses after racing, ninefold. In humans, sprint exercise produces the largest surge, resistance training a middling one, and steady endurance work the smallest. Lac-Phe is not a marker of exercise generally. It is a marker of intensity.
The functional evidence is what elevated Lac-Phe from curiosity to candidate hormone. Inject it into obese mice and they eat about half as much over the next twelve hours. Inject it daily and they lose weight, lose fat, and improve their glucose handling, all without moving less or burning more. Critically, behavioral testing found no nausea, no taste aversion, no anxiety, and no depressive signature, and no change in leptin or ghrelin. This is not a sick animal eating less. It is a satiety signal.
The brain circuit has now been mapped with unusual rigor. Lac-Phe reaches the arcuate nucleus of the hypothalamus and directly silences AgRP neurons, the cells that drive the urge to eat, by opening ATP-sensitive potassium channels. Block those channels and the appetite effect disappears. Delete AgRP neurons and it disappears. Activate them artificially and both Lac-Phe and exercise itself lose their ability to suppress feeding.
Then came the pharmacological surprise. Two independent groups reported in 2024 that metformin, the most prescribed diabetes drug on Earth, is a potent Lac-Phe inducer, and that it works through the gut epithelium rather than muscle. Mice engineered without gut CNDP2 lose weight poorly on metformin. Human mediation analyses point the same direction. A drug taken by well over 150 million people appears to have been quietly borrowing the exercise pathway all along.
The obvious ambition is a pill that reproduces the appetite effect of a sprint. That pill does not exist yet. Oral Lac-Phe is destroyed in the gut, and an orally active ester analog has only reached rats.
Actionable Insights
Three things in this literature are usable now, and one large caution applies to all of them.
Intensity, not duration, drives the signal. Sprint intervals produce the biggest Lac-Phe surge, resistance training a moderate one, and steady-state cardio the smallest. If appetite regulation is a goal, the data favor adding hard efforts rather than more easy miles.
The size of that effect: in one study, people whose Lac-Phe rose most during an exercise test lost the most abdominal fat over eight weeks of training (correlation about 0.62, meaning Lac-Phe response tracked roughly 38 percent of the variation in fat loss between individuals). On the scale researchers use for treatments, that is a standardized effect size near 1.6, where 0.8 is conventionally called large. But it is a correlation in 22 people, not proof of cause.
In mice, injected Lac-Phe produces effect sizes around 1.6 for a single dose cutting food intake and around 2.5 for ten days of dosing. For scale, most approved obesity drugs land between 0.5 and 1.2 in human trials.
Context and Source
-
Open Access Paper: Lac-Phe: An Exercise Hormone for Metabolic Regulation
-
Authors: Qingzhuo Liu and Yong Xu
-
Institution: Center for Molecular Psychiatry, Department of Psychiatry and Behavioral Neurosciences, Morsani College of Medicine, University of South Florida, Tampa, Florida
-
Country: United States
-
Journal: Annual Review of Nutrition*, 2026, volume 46, pages 153 to 175
-
Impact evaluation: The impact score of this journal is 13.4 (2024 Journal Impact Factor; CiteScore 15.4), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.